President Donald Trump announced Monday that his administration had reached new drug-pricing agreements with nine pharmaceutical companies. The companies voluntarily agreed to lower prices on certain medicines as part of the administration’s effort to align U.S. drug prices with lower prices overseas.

The participating companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceutical and UCB.

Under the agreements, the companies will provide discounts on outpatient medicines covered by state Medicaid programs, bringing certain prices in line with those charged abroad. The affected drugs treat conditions including hemophilia, liver and skin diseases, epilepsy and certain cancers.

The White House said the nine companies also committed to investing at least $19.6 billion in U.S. pharmaceutical manufacturing. Astellas, Sun Pharma, Teva and UCB will donate active pharmaceutical ingredients for critical medicines to a federal strategic reserve, helping reduce reliance on foreign suppliers. UCB, for example, will donate 163 metric tons of levetiracetam, an anticonvulsant used to prevent and control certain seizures.

The new agreements bring the total number of participating pharmaceutical companies to 26, representing about 90% of the U.S. drug market, according to Trump.

Trump revived the “most-favored-nation” drug-pricing policy through an executive order signed in May 2025. Over the past year, his administration has reached similar agreements with major pharmaceutical companies including Pfizer, Eli Lilly and Novo Nordisk.